Atara Biotherapeutics, which postponed its IPO in July upon receiving new clinical trial data, has refiled and plans sell shares in the range of $14 to $16. If priced at the range midpoint, the company would raise $75 million in the offering. Atara intends to list its shares on the NASDAQ under the symbol ATRA. Its lead candidate inhibits a muscle-growth regulating protein to prevent malnutrition, inflammation and muscle wasting in patients with chronic kidney disease or acute kidney injury. Kleiner Perkins Caufield & Byers holds the largest pre-IPO stake at 18.6%, while Domain Associates and DAG Ventures each hold 13.2%. Atara is expected to price next week.